These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

707 related articles for article (PubMed ID: 17157624)

  • 1. Hodgkin's and non-Hodgkin's lymphomas.
    Rademaker J
    Radiol Clin North Am; 2007 Jan; 45(1):69-83. PubMed ID: 17157624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.
    Qiu L; Chen Y; Wu J
    Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease.
    Spaepen K; Mortelmans L
    Q J Nucl Med; 2001 Sep; 45(3):269-73. PubMed ID: 11788819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with Non-Hodgkin lymphoma and Hodgkin's disease.
    Even-Sapir E; Lievshitz G; Perry C; Herishanu Y; Lerman H; Metser U
    Radiol Clin North Am; 2007 Jul; 45(4):697-709, vii. PubMed ID: 17706534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of positron emission tomography with [18F] 2-fluoro-D-2-deoxyglucose (FDG-PET) in Hodgkin and non-Hodgkin's lymphoma.
    Chiusolo P; Sica S; Leone G
    Hematology; 2003 Dec; 8(6):403-8. PubMed ID: 14668036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma.
    Wirth A; Seymour JF; Hicks RJ; Ware R; Fisher R; Prince M; MacManus MP; Ryan G; Januszewicz H; Wolf M
    Am J Med; 2002 Mar; 112(4):262-8. PubMed ID: 11893364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
    Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease.
    Querellou S; Valette F; Bodet-Milin C; Oudoux A; Carlier T; Harousseau JL; Chatal JF; Couturier O
    Ann Hematol; 2006 Nov; 85(11):759-67. PubMed ID: 16871391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma.
    Cheson BD
    Radiol Clin North Am; 2008 Mar; 46(2):213-23, vii. PubMed ID: 18619377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
    Specht L
    Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas.
    Kumar R; Maillard I; Schuster SJ; Alavi A
    Radiol Clin North Am; 2004 Nov; 42(6):1083-100. PubMed ID: 15488559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-FDG PET in children with lymphomas.
    Depas G; De Barsy C; Jerusalem G; Hoyoux C; Dresse MF; Fassotte MF; Paquet N; Foidart J; Rigo P; Hustinx R
    Eur J Nucl Med Mol Imaging; 2005 Jan; 32(1):31-8. PubMed ID: 15605288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management.
    Montravers F; McNamara D; Landman-Parker J; Grahek D; Kerrou K; Younsi N; Wioland M; Leverger G; Talbot JN
    Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1155-65. PubMed ID: 12192560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of interim (18)F-fluorodeoxyglucose PET to guide therapy in lymphoma.
    Araf S; Montoto S
    Future Oncol; 2013 Jun; 9(6):807-15. PubMed ID: 23718301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FDG PET as a routine test for posttherapy assessment of Hodgkin's disease and aggressive non-Hodgkin's lymphoma: where is the evidence?
    Juweid ME
    J Nucl Med; 2008 Jan; 49(1):9-12. PubMed ID: 18077522
    [No Abstract]   [Full Text] [Related]  

  • 16. [An update on recent developments in non-Hodgkin's lymphoma].
    Bouabdallah K; Milpied N
    Bull Cancer; 2007 Jan; 94(1):43-52. PubMed ID: 17237004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early prediction of response to therapy: the clinical implications in Hodgkin's and non-Hodgkin's lymphoma.
    Kostakoglu L
    Eur J Nucl Med Mol Imaging; 2008 Aug; 35(8):1413-20. PubMed ID: 18385996
    [No Abstract]   [Full Text] [Related]  

  • 18. Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease.
    Wiedmann E; Baican B; Hertel A; Baum RP; Chow KU; Knupp B; Adams S; Hör G; Hoelzer D; Mitrou PS
    Leuk Lymphoma; 1999 Aug; 34(5-6):545-51. PubMed ID: 10492078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expert opinions on positron emission tomography and computed tomography imaging in lymphoma.
    Delbeke D; Stroobants S; de Kerviler E; Gisselbrecht C; Meignan M; Conti PS
    Oncologist; 2009; 14 Suppl 2():30-40. PubMed ID: 19819922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PET imaging in pediatric Hodgkin's lymphoma.
    Hudson MM; Krasin MJ; Kaste SC
    Pediatr Radiol; 2004 Mar; 34(3):190-8. PubMed ID: 14745528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.